CN100579556C - Preparation method of Chinese medicinal capsule for treating apoplexy - Google Patents
Preparation method of Chinese medicinal capsule for treating apoplexy Download PDFInfo
- Publication number
- CN100579556C CN100579556C CN200610128269A CN200610128269A CN100579556C CN 100579556 C CN100579556 C CN 100579556C CN 200610128269 A CN200610128269 A CN 200610128269A CN 200610128269 A CN200610128269 A CN 200610128269A CN 100579556 C CN100579556 C CN 100579556C
- Authority
- CN
- China
- Prior art keywords
- radix
- group
- water
- hirudo
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a process for preparing Chinese medicinal capsules for treating apoplexy, which comprises leaching leeches, earthworm, pilose antler and buthus martensi kirsch with ethanol, weathering with warm air, disintegrating leaches into mesh fines, sterilizing with steam, disintegrating Cinnamomum cassia separately, charging water into tortoise shells, water grilling three times, filtering, merging the filter liquors, proportioning fleece-flower root, dried rehmannia root, asparagus root, broomrape, haw, radix paeoniae rubrathe, poria cocos wolf and licorice root, charging water for immersion, water grilling three times, filtering, merging the filter liquors, charging water-grilled liquid of tortoise shell, concentrating into concrete, drying till the water content is between 3-6%, charging pilose antler, buthus martensi karsch, leeches, earthworm, Cinnamomum cassia, mixing homogenously, disintegrating into fines, and loading into capsules.
Description
One, technical field
The present invention relates to a kind of production method (Chinese medicinal capsule of treatment apoplexy claims training unit logical brain capsule again) for the treatment of the Chinese medicinal capsule of apoplexy.
Two, background technology
Apoplexy is a kind of common frdquently encountered disease, clinical manifestation is hemiplegia, crooked mouth and tongue, mind unconsciousness, the stiff tongue speech is not smoothgoing or in silence, hemianesthesia, having a strong impact on the healthy and life security of people, therefore, people are concerned about the prevention of apoplexy and treatment very much, traditional medicine thinks that the main cause of apoplectic hemiplegia is that QI and blood is unclear, kidney unit loses empty, obstruction of collaterals by blood stasis, and " cerebrovascular " is out of joint; Therefore Chinese medicine blood circulation promoting and blood stasis dispelling, blood fat reducing, or the method for Western medicine blood vessel dilating are adopted in treatment more.Modern medicine study shows that the pathological changes of " cerebrovascular " is the inducement of apoplexy, and the basic reason of apoplectic hemiplegia is to increase owing to cranial nerve cell toxicity that cerebral hemorrhage or ischemia cause, causes cranial nerve impaired, thereby causes symptom such as hemiplegia aphasia.This disease of treatment has acupuncture, massage, suitably tempers, takes medicine etc. at present, with medicine Western medicine and Chinese medicine are arranged, as train the logical brain capsule of unit etc., but for various reasons, as train the logical brain capsule of unit, because the problem that exists in producing, pharmaceutical effectiveness is unsatisfactory, do not satisfy the actual needs of people to the treatment apoplexy, its improvement is imperative.
Three, summary of the invention
At present actual needs to the treatment apoplexy, the present invention's purpose just provides a kind of production method for the treatment of the Chinese medicinal capsule of apoplexy, can effectively solve the medication production problem of apoplexy, the technical scheme of its solution is, adopt Radix Polygoni Multiflori, Radix Rehmanniae, Radix Asparagi, Carapax Et Plastrum Testudinis, Cornu Cervi Pantotrichum, Herba Cistanches, Cortex Cinnamomi, Radix Paeoniae Rubra, Scorpio, Hirudo, Pheretima, Fructus Crataegi, Poria and Radix Glycyrrhizae, Hirudo wherein, Pheretima, Cornu Cervi Pantotrichum and Scorpio are respectively earlier with the quick drip washing 2-3 of 75% ethanol time, again at 60-70 ℃ of hot blast drying, pulverize respectively afterwards, Hirudo adopts micronizing to reach the homogeneous fine powder of 95% above yield, after the pulverizing, under 115-130 ℃, carry out steam sterilization, keep effective ingredient to greatest extent to reach, and sterilization thoroughly, ensure drug quality, improve effective percentage, Cortex Cinnamomi is ground into fine powder separately; Carapax Et Plastrum Testudinis adds water, decocts three times, filters, merging filtrate, Radix Polygoni Multiflori, Radix Rehmanniae, Radix Asparagi, Herba Cistanches, Fructus Crataegi, Radix Paeoniae Rubra, Poria and Radix Glycyrrhizae are mixed and add water together, soak, decoct three times, filter merging filtrate, add Carapax Et Plastrum Testudinis decocting liquid again, simmer down to extractum is dried to water content when 3-6%, add Cornu Cervi Pantotrichum again, Scorpio, Hirudo, Pheretima, the Cortex Cinnamomi powder, mixing is ground into fine powder, incapsulates, the inventive method advanced person, science, flour extraction height, the easy stripping of effective ingredient, improve active constituent content, sterilization is thoroughly avoided the moist influence to medicated powder end moisture and quality of row of extractum, good product quality, the curative effect height, take safety, easily promote the use of, benefit people.
Four, the specific embodiment
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Provide by technical scheme, the present invention adopts: Radix Polygoni Multiflori 429g, Radix Rehmanniae 286g, Radix Asparagi 286g, Carapax Et Plastrum Testudinis 46g, Cornu Cervi Pantotrichum 23g, Herba Cistanches 114g, Cortex Cinnamomi 24g, Radix Paeoniae Rubra 49g, Scorpio 48g, Hirudo 96g, Pheretima 49g, Fructus Crataegi 142g, Poria 48g and Radix Glycyrrhizae 29g make, with Cornu Cervi Pantotrichum, Scorpio, Hirudo, Pheretima is respectively earlier with the quick drip washing 2-3 of 75% ethanol time, again at 60-70 ℃ of hot blast drying, afterwards respectively with Cornu Cervi Pantotrichum, Scorpio, Pheretima powder is broken into fine powder, sieve, Hirudo fibre-bearing arc, adopt micronizing to reach and receive the powder rate more than 95%, the fine powder homogeneous, medicated powder after the above-mentioned pulverizing carries out steam sterilization under 115-130 ℃, keep effective ingredient to greatest extent to reach, thoroughly sterilization improves curative effect, sieves; It is standby that Cortex Cinnamomi powder is broken into fine powder; Carapax Et Plastrum Testudinis decocts with water three times, the water (being 368ml) that adds for the first time 8 times of bulking values, fried in shallow oil 6 hours, second, respectively add the water (being 276ml) of 6 times of bulking values for the third time, fried in shallow oil 4.5 hours, filter, merging filtrate, again with Radix Polygoni Multiflori, Radix Rehmanniae, Radix Asparagi, Herba Cistanches, Radix Paeoniae Rubra, Fructus Crataegi, Poria and Radix Glycyrrhizae mix, and the water (being 8298ml) that adds 6 times of bulking values soaked 1 hour, decocted three times, each 1.5 hours, filter, merging filtrate adds Carapax Et Plastrum Testudinis decocting liquid again, be condensed into relative density and be 1.2 extractum, be dried to water content again when 3-6%, add Cornu Cervi Pantotrichum, Scorpio, Hirudo, Pheretima and Cortex Cinnamomi powder mix and pulverize evenly, divide the capsule of packing into, powder charge thing 0.6g in every capsule can add appropriate amount of starch, corning in case of necessity.
In said medicine, wherein Radix Polygoni Multiflori is a Radix Polygoni Multiflori Preparata; Radix Rehmanniae is a Radix Rehmanniae Preparata; Carapax Et Plastrum Testudinis is a Carapax et Plastrum Testudinis(processed with vinegar); Herba Cistanches is the processed with wine Herba Cistanches; Hirudo is for scalding Hirudo; Fructus Crataegi is a Fructus Crataegi (parched); Radix Glycyrrhizae is a Radix Glycyrrhizae Preparata.
Can make the Chinese medicinal capsule of any amount with above-mentioned component compatibility amount and method.
Said said medicine, wherein Radix Polygoni Multiflori Preparata: have invigorating the liver and kidney, benefiting essence-blood, black beard and hair, effects such as strong muscle; Radix Rehmanniae Preparata: nourishing YIN and supplementing blood, marrow is filled out in lung heat clearing; Radix Asparagi: nourishing YIN to relieve dryness, lung heat clearing is promoted the production of body fluid; Carapax Et Plastrum Testudinis: nourishing YIN for suppressing the hyperactive YANG, kidney tonifying bone strengthening, the reinforcing the heart of nourishing blood; Cornu Cervi Pantotrichum: invigorating kidney-YANG, benefiting essence-blood, bone and muscle strengthening; Herba Cistanches: kidney-replenishing, benefiting essence-blood, loosening bowel to relieve constipation; Cortex Cinnamomi: warming middle-JIAO YANG invigorating, dispersing cold for relieving pain, promoting blood circulation to restore menstrual flow; Radix Paeoniae Rubra: clearing away heat and cooling blood, eliminating stasis to stop pain; Scorpio: endogenous wind stopping spasmolytic, dispersing pathogen accumulation, removing obstruction in the collateral to relieve pain; Hirudo: removing blood stasis, removing blood stasis stimulates the menstrual flow; Pheretima: the heat clearing away arresting convulsion, collateral dredging is relievingd asthma, diuresis; Fructus Crataegi: promoting digestion and invigorating the stomach, circulation of qi promoting dissipating blood stasis; Poria: promoting diuresis to eliminate damp pathogen, spleen invigorating mind calming; Radix Glycyrrhizae: invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, nourishing the lung to arrest cough, coordinating the actions of various ingredients in a prescription.
By said medicine as can be known, its science compatibility has blood circulation promoting and blood stasis dispelling, blood fat reducing, the effect of blood vessel dilating, through the science preparation, change traditional preparation method again, adopted animal class component especially, use ethanol drip washing, independent hot blast drying, pulverize, add medicated powder again after the independent drying of steam sterilization and extractum, both guaranteed the raising of effective ingredient, avoid the moist influence of drawing of extractum mixed-powder moisture and quality, guarantee degree of drying and medicated powder quality, improve curative effect, better guaranteed the quality of medicine, more effectively treated apoplexy (cerebral thrombosis), and fully obtaining the proof of clinical treatment, its concrete clinical data is as follows.
One, diagnostic criteria
(1) abideing by " new Chinese medicine clinical research guideline " standard carries out
1. primary symptom: hemiplegia, crooked mouth and tongue, the mind unconsciousness, the stiff tongue speech is not smoothgoing or in silence, hemianesthesia.2. Acute onset.3. sick sending out has inducement more, and premorbid does not often have premonitory symptom.4. it is many more than 40 years old to send out the age well.
Have primary symptom more than 2, Acute onset can be determined diagnosis in conjunction with the characteristics of aspects such as tongue, arteries and veins, inducement, tendency, age.
(2) Chinese medical discrimination standard (, drafting) in conjunction with " the dialectical reference standard of Chinese medicine deficiency-syndrome " nephrasthenia syndrome diagnostic criteria, " syndrome of blood stasis diagnostic criteria " with reference to five editions teaching materials of unified editing " Chinese Internal Medicine apoplexy " deficiency of kidney essence card:
Kidney unit loses empty, syndrome of static blood blocking collaterals: possess kidney unit simultaneously and lose deficiency syndrome and syndrome of static blood blocking collaterals diagnostic criteria.
Kidney unit loses deficiency syndrome: 1. say silent aphasia; 2. soreness of the waist and knees; 3. tinnitus or deafness; 4. behind the urine heeltap or incontinence are arranged; 5. pale tongue, white and thin fur, deep-thready pulse.Below 1. indispensable, possess simultaneously 2.～in 5. 2.
Syndrome of static blood blocking collaterals: 1. hemiplegia; 2. hemianesthesia; 3. purplish tongue or ecchymosis, point, hesitant pulse are arranged.Below 1. indispensable, possess simultaneously 2.～in 3. 1.
(3) apoplexy standard by stages: 1. acute stage: morbidity is in 2 weeks, and middle internal organs grow to 1 month most.2. convalescent period: fell ill for 2 thoughtful half a year.3. sequela stage: more than morbidity half a year.
The Western medicine diagnose standard:
Cerebral thrombosis (abideing by " new Chinese medicine clinical research guideline " standard carries out): 1. often under rest state, fall ill.2. great majority do not have obviously headache and vomiting.3. morbidity can be slower, and how gradually progress, or stage carries out, and is how relevant with cerebral atherosclerosis, also is found in arteritis, hematopathy etc.4. the clear or slight obstacle of consciousness in general morbidity back 1-2 day.5. internal carotid artery system and/or vertebral basilar system sings and symptoms are arranged.6. waist is worn cerebrospinal fluid and generally should do not contained blood.7. CT examination is found cerebral location of lesions.
Two, case choice criteria
Meet following patient simultaneously at 4, can include the test case in.1. meet apoplexy diagnostic criteria person.2. apoplexy meets convalescent period or sequela stage person by stages.3. Chinese medical discrimination meets kidney unit thanks to void, obstruction of collaterals by blood stasis person.4. the Western medicine diagnose person that meets the cerebral thrombosis.
Three, treatment (test) scheme
First group and second group adopt completely random grouping, double blinding dual analog counter point, and open group adopts self cross-reference.
1, the card of establishment random assortment earlier:
(1) according to the result of computer random number keyboard, to fill in order and distribute card, its content comprises: sequence number, random digit, group (two groups of branch first, second), Therapeutic Method.
(2) the random assortment card seals with envelope, and its numbering is identical with the card sequence number.
(3) the random assortment card is by special messenger's keeping, and other people must not participate in evaluation of clinical curative effect, and clinical observation and therapeutic evaluation personnel must not participate in filling in and keeping of random assortment card.
2, preparation medicine: the logical brain capsule of preparation training unit is No. 1, No. 2 as requested, and in the two, a kind of another kind is a placebo in order to observe medicine, and both require outward appearance, shape, size, abnormal smells from the patient, color and dose all in full accord; PIANTAN FUYUAN WAN No. 1, No. 2, in the two, a kind of another kind is a placebo in order to contrast medicine, both also require outward appearance, shape, size, abnormal smells from the patient, color and dose all in full accord.The flesh and blood of these four kinds of medicine numberings is responsible for by the special messenger, all maintains secrecy to clinical observation person and patient.The logical brain capsule of training unit that preparation is not simultaneously numbered is used for open group.The logical brain capsule of training unit is capsule of the present invention (as follows).
3, the enforcement of double-blind method:
(1) enter when research as qualified experimenter, enter order by random assortment card custodian by it and take the identical envelope of sequence number apart, according to the regulation grouping of card wherein with treat, anyone must not change, and its Therapeutic Method must not make observer and experimenter learn.
(2) consistent as far as possible between first group and the second group at aspects such as sex, age, disease time, the state of an illness and the courses of disease.
(3) first group medication: No. 1, the logical brain capsule of training unit, oral, 3/time, 3 times/day; No. 2, oral PIANTAN FUYUAN WAN simultaneously, 6 grams/time, 3 times/day.
(4) second group medication: No. 1, PIANTAN FUYUAN WAN, oral, 6 grams/time, 2 times/day; No. 2, the logical brain capsule of simultaneously oral training unit, 3/time, 3 times/day
Viewing duration, two groups of first, second all without other to the medicative medicine of apoplexy sequela.
(5) course of treatment: the observation course of treatment of first group and second group, equal 6 weeks (42 days).
(6) observe to finish after, by responsible person clinical data is gathered and statistical procedures, the curative effect and the clinical meaning of first and second liang of groups compared; And then take off blindly by the special messenger who is responsible for the medicine numbering, and announce which group is the treatment group, which group is matched group; The ultimate analysis clinical effectiveness.
(7) take off blind condition: meet following any one and promptly take off blind.Obvious toxicity appears in the 1. viewing duration, first and second liang of groups arbitrary group, observe and be difficult to into passerby; 2. after observing end, clinical data has passed through edit, has write out and observe brief summary first draft person.
4, the medication of open group:
Only with the logical brain capsule of training unit of not numbering, 3/time, 3 times/day.Viewing duration, without other to the medicative medicine of apoplexy sequela.Observing the course of treatment is 6 weeks (42 days).
Four, efficacy assessment standard
Adopt the nimodipine method:
1. be almost recovered: 〉=85%.2. produce effects: 〉=50%.3. effective: 〉=20%.4. invalid:＜20%.
The apoplexy point system
1. the mind state is 0 minute: sanity.1 minute: staring spells (drowsy, energy and people's words after waking up).2 minutes: mind mist (drowsiness, answering of exhaling is imprecise).3 minutes: coma.4 minutes: refreshing muddled (coma has concurrently simultaneously and takes off disease).
2. language performance is 0 minute: normal.1 minute: the general expression, name could not.2 minutes: form a complete sentence in a minute and express incomplete.3 minutes: not talkative word, phrase.4 minutes: language can not or substantially can not.
3. the upper limb shoulder joint is 0 minute: normal.1 minute: last act was normal but muscular strength is poor.2 minutes: go up and lift flat shoulder or skip over shoulder.3 minutes: go up and lift less than shoulder.4 minutes: inactive or slightly swing of front and back.
4. the upper limb articulations digitorum manus is 0 minute: normal.1 minute: finger moves respectively effectively but muscular strength is poor.2 minutes: can clench fist and stretch finger.3 minutes: can count on one's fingers but can not hold fist, can not stretch finger.4 minutes: point inactive.
5. the lower limb hip joint is 0 minute: normal.1 minute: raise more than 45 degree.2 minutes: raise less than 45 degree.3 minutes: swing can translation.4 minutes: inactive.
6. the lower limb toe joint is 0 minute: normal.1 minute: stretch and bend freely but a little less than the power.2 minutes: stretch Qu Buquan.3 minutes: slightly active.4 minutes: inactive.
7. comprehensive function is 0 minute: take care of oneself open.1 minute: live on one's own life simple work and have partial function incomplete.2 minutes: can walk, partial self-help, the people that still needs is auxiliary.3 minutes: can stand and take a step, need the people to take care of at any time.4 minutes: bed.
Five, statistical procedures
1, the total curative effect of apoplexy: in first group 64 examples, 10 examples that are almost recovered, produce effects 39 examples, effective 10 examples, invalid 5 examples, total obvious effective rate 76.56%, total effective 92.19%; In second group 60 examples, 6 examples that are almost recovered, produce effects 27 examples, effective 16 examples, invalid 11 examples, total obvious effective rate 55.00%, total effective rate 81.67%; In open group 97 examples, 7 examples that are almost recovered, produce effects 56 examples, effective 24 examples, invalid 10 examples, total obvious effective rate 64.95%, total effective rate 89.69% (seeing the following form).Above result shows that relatively, total obvious effective rate has statistical significance (P＜0.05) between first and second liang of group groups.The total curative effect of prompting first group treatment apoplexy is better than the second group.
Table 1 is respectively organized the comparison of apoplexy total effects
| Group | The example number | (example) is almost recovered | Produce effects (example) | Effectively (example) | Invalid (example) | Total obvious effective rate | Total effective rate |
| The first group | 64 | 10 | 39 | 10 | 5 | 0.7656 | 0.9219 |
| The second group | 60 | 6 | 27 | 16 | 11 | 0.5500 | 0.8167 |
| Open group | 97 | 7 | 56 | 24 | 10 | 0.6495 | 0.8969 |
Annotate: compare between the group of first and second liang of total obvious effective rates of group: X
2=6.4282, P＜0.05
Compare between the group of first and second liang of group total effective rates: X
2=3.0501, P＞0.05
2, the comparison of three groups of apoplexy score score values: three groups of apoplexy score score values (seeing Table 2), compare not statistically significant (P＞0.05) between group before first and second liang of group treatments, show and have comparability: self compares before and after the treatment, three groups all have statistical significance (P＜0.01), point out three groups all can obviously improve apoplexy score score value.Between the group of first and second liang of group treatment front and back score differences statistical significance (P＜0.05) is arranged relatively, prompting first group is better than the second group to the improvement of apoplexy score score value.
Table 2 is respectively organized the comparison of the score score value of apoplexy
| Group | The example number | Score value before the treatment (X ± S) | Treatment back score value (X ± S) | Last difference (X ± S) |
| The first group | 64 | 13.234±4.2417 | 5.7031±3.9868 | -7.531±3.7458 |
| The second group | 60 | 12.117±4.8015 | 6.3167±4.2085 | -5.800±3.7408 |
| Open group | 97 | 14.010±5.1041 | 6.4639±4.4583 | -7.546±4.4112 |
Annotate: compare between the group of first and second liang of preceding score values of group treatment: t=1.3758, P＞0.05
Self compares front and back: first group t=16.085, P＜0.01; Second group t=12.010, P＜0.01;
Open group t=16.849, P＜0.01
Compare between the group of first and second liang of group treatment front and back differences: t=2.5737, P＜0.05
3, middle kidney unit loses curative effect empty, syndrome of static blood blocking collaterals:
(1) to traditional Chinese medical science therapeutic effect of syndrome: in first group 64 examples, 5 examples that are almost recovered, produce effects 27 examples, effective 25 examples, invalid 7 examples, total obvious effective rate 50.00%, total effective rate 89.06%; In second group 60 examples, 5 examples that are almost recovered, produce effects 16 examples, effective 26 examples, invalid 13 examples, total obvious effective rate 35.00%, total effective rate 78.33%; In open group 97 examples, 6 examples that are almost recovered, produce effects 31 examples, effective 51 examples, invalid 9 examples, total obvious effective rate 38.14%, total effective rate 90.72% (seeing Table 5).Above result shows, compares between first and second liang of group groups, total obvious effective rate and the equal not statistically significant of total effective rate (P＞0.05), and group treatment kidney unit is thanks to empty, blood stasis group network therapeutic effect of syndrome is suitable to point out first and second liang.
Table 3 is respectively organized kidney unit and is lost comparison empty, blood stasis group network therapeutic effect of syndrome
| Group | The example number | (example) is almost recovered | Produce effects (example) | Effectively (example) | Invalid (example) | Total obvious effective rate | Total effective rate |
| The first group | 64 | 5 | 27 | 25 | 7 | 0.5000 | 0.8906 |
| The second group | 60 | 5 | 16 | 26 | 13 | 0.3500 | 0.7833 |
| Open group | 97 | 6 | 31 | 51 | 9 | 0.3814 | 0.9072 |
Annotate: compare between the group of first and second liang of total obvious effective rates of group: X
2=2.2131, P＞0.05
Compare between the group of first and second liang of group total effective rates: X
2=0.1186, P＞0.05
(2) three groups of kidney units lose comparison empty, that the obstruction of collaterals by blood stasis syndrome is scored score value: three groups of kidney units lose empty, obstruction of collaterals by blood stasis syndrome score score value (seeing Table 4), treat and compare not statistically significant (P＞0.05) between preceding first and second liang of group groups, show tool comparability between group; Self compares before and after the treatment, and three groups all have statistical significance (P＜0.01), points out three groups all can obviously improve first thanks to empty, the syndrome of static blood blocking collaterals score score value of kidney; Between the group of first and second liang of group treatment front and back score differences statistical significance (P＜0.05) is arranged relatively, prompting first group is better than the second group to the improvement that kidney unit loses void, syndrome of static blood blocking collaterals score score value.
Table 4 is respectively organized kidney unit and is lost comparison empty, syndrome of static blood blocking collaterals score score value
| Group | The example number | Score value before the treatment (X ± S) | Treatment back score value (X ± S) | Last difference (X ± S) |
| The first group | 64 | 10.734±3.7932 | 4.3906±2.7801 | -6.344±3.0353 |
| The second group | 60 | 9.950±3.7751 | 4.7667±3.2903 | -5.183±3.0337 |
| Open group | 97 | 10.825±3.4731 | 4.6289±2.9130 | -6.196±2.8345 |
Annotate: compare between the group of first and second liang of preceding score values of group treatment: t=1.1534, P＞0.05
Self compares front and back: first group t=16.720, P＜0.01; Second group t=13.325, P＜0.01;
Open group t=21.529, P＜0.01
Compare between the group of first and second liang of group treatment front and back differences; T=2.1280, P＜0.05
(3) variation of three groups of picture of the tongues of table 5, pulse condition: the variation (seeing the following form 5) of three groups of picture of the tongues, pulse condition
Annotate: compare before and after self: P＞0.05
Compare P＞0.05 between first and second liang of group groups
5, blood is filled the influence that becomes: see Table 6, wherein the whole blood height is cut with whole blood is low and is cut, and the first group self more all has statistical significance (P＜0.01) before and after treating with open group, points out two groups certain effect that improves hemorheology is arranged
Each group of table 6 is to hemorheological influence
Annotate: front and back self are P＞0.05 relatively, P＜0.05, P＜0.01
Compare between first and second liang of group groups: P＞0.05, P＜0.05
Six, conclusion
By above-mentioned situation as can be seen, the medicine that the present invention produces is a kind of treatment apoplexy (cerebral thrombosis) first active drug that loses void, syndrome of static blood blocking collaterals of kidney of convalescent period, not only be better than existing similar drug, and there is not an obvious toxic action, outstanding clinical meaning and application value are arranged, make and benefit society.
Claims (1)
1, a kind of production method for the treatment of the Chinese medicinal capsule of apoplexy, it is characterized in that, adopt: Radix Polygoni Multiflori 429g, Radix Rehmanniae 286g, Radix Asparagi 286g, Carapax Et Plastrum Testudinis 46g, Cornu Cervi Pantotrichum 23g, Herba Cistanches 114g, Cortex Cinnamomi 24g, Radix Paeoniae Rubra 49g, Scorpio 48g, Hirudo 96g, Pheretima 49g, Fructus Crataegi 142g, Poria 48g and Radix Glycyrrhizae 29g make, with Cornu Cervi Pantotrichum, Scorpio, Hirudo, Pheretima is respectively earlier with the quick drip washing 2-3 of 75% ethanol time, again at 60-70 ℃ of hot blast drying, afterwards respectively with Cornu Cervi Pantotrichum, Scorpio, Pheretima powder is broken into fine powder, sieve, Hirudo is adopted micronizing to reach and receives the powder rate more than 95%, the fine powder homogeneous, medicated powder after the above-mentioned pulverizing carries out steam sterilization under 115-130 ℃, keep effective ingredient to greatest extent to reach, thoroughly sterilization improves curative effect, sieves; It is standby that Cortex Cinnamomi powder is broken into fine powder; Carapax Et Plastrum Testudinis decocts with water three times, add for the first time the water of 8 times of bulking values, fried in shallow oil second 6 hours, the water that respectively adds 6 times of bulking values for the third time, fried in shallow oil 4.5 hours, filter, merging filtrate is again with Radix Polygoni Multiflori, Radix Rehmanniae, Radix Asparagi, Herba Cistanches, Radix Paeoniae Rubra, Fructus Crataegi, Poria and Radix Glycyrrhizae add the water logging of 6 times of bulking values and steeped 1 hour, decoct three times, each 1.5 hours, filter merging filtrate, add Carapax Et Plastrum Testudinis decocting liquid again, concentrate drying to water content when the 3-6%, add Cornu Cervi Pantotrichum, Scorpio, Hirudo, Pheretima and Cortex Cinnamomi powder mix and pulverize evenly, divide the capsule of packing into, powder charge thing 0.6g in every capsule can add appropriate amount of starch, corning in case of necessity; Said Radix Polygoni Multiflori is a Radix Polygoni Multiflori Preparata, and Radix Rehmanniae is a Radix Rehmanniae Preparata, and Carapax Et Plastrum Testudinis is a Carapax et Plastrum Testudinis(processed with vinegar), and Herba Cistanches is the processed with wine Herba Cistanches, and Hirudo is for scalding Hirudo, and Fructus Crataegi is a Fructus Crataegi (parched), and Radix Glycyrrhizae is a Radix Glycyrrhizae Preparata.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610128269A CN100579556C (en) | 2006-11-24 | 2006-11-24 | Preparation method of Chinese medicinal capsule for treating apoplexy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610128269A CN100579556C (en) | 2006-11-24 | 2006-11-24 | Preparation method of Chinese medicinal capsule for treating apoplexy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1965996A CN1965996A (en) | 2007-05-23 |
| CN100579556C true CN100579556C (en) | 2010-01-13 |
Family
ID=38075089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200610128269A Active CN100579556C (en) | 2006-11-24 | 2006-11-24 | Preparation method of Chinese medicinal capsule for treating apoplexy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100579556C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552660A (en) * | 2010-12-24 | 2012-07-11 | 河南羚锐制药股份有限公司 | Novel application of Chinese medicinal composition to treatment of pseudobulbar palsy |
| CN102526453A (en) * | 2010-12-24 | 2012-07-04 | 河南羚锐制药股份有限公司 | New application of supporting and brain-promoting medicinal composition to treatment of elevated serum lipid |
| CN102068595A (en) * | 2010-12-24 | 2011-05-25 | 河南羚锐制药股份有限公司 | New application of Chinese medicinal composition to treatment of vascular dementia |
| CN102614360A (en) * | 2010-12-24 | 2012-08-01 | 河南羚锐制药股份有限公司 | Novel application of traditional Chinese medicine combination to treating vascular dementia |
| CN104258022A (en) * | 2014-10-13 | 2015-01-07 | 河南羚锐制药股份有限公司 | Production technology of traditional Chinese medicine for treating kidney deficiency and blood-stasis obstruction syndromes in meridian recovery period of ischemic stroke |
| CN111920921B (en) * | 2020-09-14 | 2022-03-08 | 河南中医药大学 | Seven-worm compound traditional Chinese medicine for treating stroke |
-
2006
- 2006-11-24 CN CN200610128269A patent/CN100579556C/en active Active
Non-Patent Citations (2)
| Title |
|---|
| 《国家新药注册数据1985-2000》（光盘）. 国家药品监督管理局药品审评中心，电子工业出版社. 2001 |
| 《国家新药注册数据1985-2000》(光盘). 国家药品监督管理局药品审评中心，电子工业出版社. 2001 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1965996A (en) | 2007-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104147284B (en) | Chinese herbal preparation for treating epilepsy and preparation method thereof | |
| CN100579556C (en) | Preparation method of Chinese medicinal capsule for treating apoplexy | |
| CN104096176A (en) | Traditional Chinese medicine for treating anxiety, and preparation method | |
| CN103565969B (en) | Traditional Chinese medicine composition for treating soft tissue injury and fracture | |
| CN105362491A (en) | External-use medicine for treating cervical vertebra hyperosteogeny | |
| CN104491236A (en) | Traditional Chinese medicine preparation for treating essential hypertension and preparation method for traditional Chinese medicine preparation | |
| CN104606561A (en) | Traditional Chinese medicinal composition for treating spontaneous perspiration | |
| CN104825956A (en) | Medicine for preventing and treating stroke and recovering muscles, bones and joints | |
| CN104524479B (en) | A kind of Chinese medicine composition for treating premenstrual syndrome and preparation method thereof | |
| CN107617081B (en) | Traditional Chinese medicine composition for treating alopecia and preparation method thereof | |
| CN102961561B (en) | Chinese medicinal composition for treating coronary heart disease | |
| CN112451601A (en) | Comprehensive prevention and treatment medicine for middle-aged and elderly chronic diseases | |
| CN104888133A (en) | Traditional Chinese medicine composition for treatment of coronary heart disease | |
| CN1723933A (en) | Traditional Chinese medicine capsule for treating application, and its prodn. method | |
| CN104189587A (en) | Traditional Chinese medicine preparation capable of nourishing yin and suppressing excessive yang for treating epilepsy and preparation method of traditional Chinese medicine preparation | |
| CN104096018A (en) | Traditional Chinese medicine composition for treating facial neural paralysis | |
| CN102579757B (en) | Anti-aging Chinese medicine composition in separation medicine and moxibustion umbilicus mode | |
| CN102626503B (en) | Chinese medicinal oral liquid for smoothing heart and enhancing intelligence | |
| CN100406035C (en) | Chinese medicine preparation for treating protrasion of lumbar intervertebral disc | |
| CN105998738A (en) | Traditional Chinese medicinal composition for treating night sweat | |
| CN105233076A (en) | Preparing method for traditional Chinese medicine for preventing and treating blurred vision | |
| CN104707031A (en) | Traditional Chinese medicine composition for treating senile osteoporosis and preparation method thereof | |
| CN105106786A (en) | Traditional Chinese medicine composition capable of dredging collaterals and relaxing muscles as well as preparation and production method of composition | |
| CN104491237A (en) | Use of traditional Chinese medicine preparation in preparing medicines for treating primary hypertension | |
| CN103990044A (en) | Traditional Chinese medicinal composition for treating epilepsy, as well as preparation method, preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder |
Address after: 465550 No. 666 General Road, Xinxian County, Henan Province Patentee after: Henan Lingrui Pharmaceutical Co., Ltd. Address before: 465550 Henan Lingrui Pharmaceutical Co., Ltd. Xinxian Henan Province Patentee before: Henan Lingrui Pharmaceutical Co., Ltd. |
|
| CP02 | Change in the address of a patent holder |